Serratiopeptidase Information, dosage, 20,000 units or 40,000 units? Health benefit and side effects of Serratiopeptidase enzyme
Serratiopeptidase, an enzyme
isolated from a microorganism in silkworm, is widely used in clinical practice
in Japan. Until more is known about the long term benefit and side effects of
serratiopeptidase, we recommend limiting daily dose to 20,000 units. We also
suggest you take days off, for instance one day off a week and a few days off
each month. Future research will give us clearer ideas of the ideal dosage of
this supplement and more information on its safety profile.
SerratioPeptidase
Enteric Coated - pH Resistant
Manufactured by a FDA approved and GMP certified facility.
The silkworm has
serrapeptase (also known as Serratio Peptidase or serratiopeptidase),
a proteolytic enzyme. This enteric coated
serratiopeptidase
product by Physician
Formulas is of the highest quality available. It is
manufactured by a FDA approved facility. You can be sure you are getting exactly
what you pay for.
Serratiopeptidase, isolated from the microorganism Serratia E15,
is
naturally present in the silkworm intestine which allows the emerging moth to
dissolve its cocoon. Clinical use of
serratiopeptidase
in Europe and Asia spans over
twenty five years.
Serrapeptase Supplement Facts
Serrapeptase - 200mg*
SerratioPeptidase
(20,000 units enteric coated granules - 120,000
units per gram)
Click here to buy serratiopeptidase
or to sign up to a FREE newsletter
* Serratiopeptidase daily value not established.
Serratiopeptidase
summary
Serratiopeptidase
appears to be a supplement with some clinical potential,
however much more research is needed before we determine what clinical role this
enzyme has in medicine. In the meantime, only use
serratiopeptidase
under medical
supervision until more studies determine the full spectrum of
serratiopeptidase
side
effects and benefits.
Conditions where serratiopeptidase has been studied
Chronic airway lung disease
Chronic ear, nose or throat disorders
Carpal tunnel syndrome
Serratiopeptidase has even been studied in certain cases of edema after an operation
or injury.
Serratiopeptidase not
helpful for dental pain
A randomized, double-blind, placebo-controlled
study comparing the efficacy and safety of paracetamol, serratiopeptidase,
ibuprofen and betamethasone using the dental impaction pain model.
Int J Oral Maxillofac Surg. 2009 Jan 23. Chopra D, Rehan HS, Mehra P, Kakkar
AK. Department of Pharmacology, Lady Hardinge Medical College, New Delhi, India.
Assessment of postoperative sequelae following the removal of an impacted
third molar tooth has been used in clinical pharmacology to evaluate the
relative efficacy of various analgesic, anti-inflammatory drugs. This study
included 150 patients with impacted lower third molars. They were randomly
sorted to receive ibuprofen, paracetamol, betamethasone, serratiopeptidase or
placebo. Betamethasone showed significant analgesic activity from day 1.
Ibuprofen and betamethasone were significantly more effective than placebo in
reducing swelling. Serratiopeptidase did not show significant analgesic and
anti-inflammatory action.
Serratiopeptidase Research studies
Effect of the proteolytic enzyme serratiopeptidase in patients with chronic airway
disease.
Respirology. 2003 Sep;8(3):316-20.
The proteolytic enzyme serratiopeptidase is widely used in clinical
practice in Japan. We investigated the effect of serrapeptase on sputum properties and
symptoms in patients with chronic airway diseases. This study was an
open-labeled trial with a non-treatment control group. Patients were randomly
assigned to oral treatment and without serratiopeptidase 30 mg/day for
4 weeks. Patients collected sputum samples for about 4 hours in the morning on the
day the trial began and 4 weeks later. Part of each sputum sample was weighed and then completely dried and
reweighed. The percentage solid component, viscosity and elasticity of the
sputum were measured. Mucociliary transportability index was measured using
ciliated bovine trachea ex vivo. After 4 weeks of serratiopeptidase treatment, sputum
weight in the morning, percentage solid component, viscosity and elasticity of
sputum, sputum neutrophil count, frequency of coughing and frequency of
expectoration significantly decreased. CONCLUSIONS: serratiopeptidase may exert a beneficial effect on mucus clearance by reducing neutrophil numbers
and altering the viscoelasticity of sputum in patients with chronic airway
diseases.
A preliminary trial of serratiopeptidase in patients with carpal tunnel
syndrome.
J Assoc Physicians India. 1999 Dec;47(12):1170-2.
This study was planned to assess the response of serratiopeptidase in
patients with carpal tunnel syndrome (CTS). Twenty patients with CTS were
evaluated clinically. After baseline electrophysiological studies, these
patients were given serrapeptase 10 mg twice daily with initial short
course of nimesulide. Clinical and electrophysiological reassessment was done
after 6 weeks. Sixty five percent of
serratiopeptidase
cases showed significant clinical
improvement which was supported by improvement in
electrophysiological parameters. Recurrence was reported in four cases. No
significant side effect was observed. CONCLUSIONS:
serratiopeptidase
therapy may
proved to be a useful alternative mode of conservative treatment. Larger study
may be further helpful to establish the role of
serratiopeptidase
in CTS.
Serratiopeptidase therapy.
Q. I have been looking into the use of
serratiopeptidase
during my pregnancy to help with some varicose veins that
have developed. My midwives said it is a completely natural product, but they
see no studies supporting the safety of its use during pregnancy. Do you have
any information regarding this, or could you direct me?
A. We have not seen any studies regarding the safety of
serratiopeptidase during pregnancy.
home Passion Rx vitamins, herbal formulas
Formulation optimization of
serratiopeptidase loaded PLGA microspheres using selected variables.
PDA J Pharm Sci Technol. 2009 Mar-Apr; Singh D, Dixit VK, Saraf S, Saraf S.
Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, India.
Serratiopeptidase-loaded poly (D,L-lactic-co-glycolic acid) (PLGA)
microspheres were prepared using the modified double emulsion method. The effect
of polymer concentration and external aqueous phase volume on microsphere size
and entrapment efficiency was studied by 3(2) full factorial experiments. The
results of analysis of variance test for measured responses indicated the test's
significance. The contribution of PLGA concentration on microsphere size and
percentage yield was found to be higher than that of external aqueous phase
volume, which produced a significant effect on entrapment efficiency.
Microspheres demonstrated spherical particles in the size range of 19.08-41.14
microm and entrapment efficiency between 15 and 79%. The formulation using a
medium level of polymer and a low level of external aqueous phase (PLGA: 300 mg;
EAP: 100 mL) showed maximum entrapment. The in vitro release profile of all
formulations demonstrated a similar sustained release showing an initial burst
followed by diffusion. The bioactivity of the peptide remained intact after
microencapsulation as assayed by in vitro proteolytic activity. Response surface
graphs are presented to examine the effects of independent variables on the
responses studied. In conclusion, controlled-release serratiopeptidase loaded
PLGA microspheres demonstrating maximum entrapment were successfully prepared by
an experimental design methodology with a minimum number of runs, representing
an economical approach.